Transmission of S230R integrase drug resistance mutation affecting second-generation integrase inhibitors in a French primary HIV-1 infected man

J Antimicrob Chemother. 2023 Jul 5;78(7):1802-1803. doi: 10.1093/jac/dkad135.

Authors

Maud Salmona^{1

2}, Caroline Lascoux-Combe³, Marie Laure Nere¹, Emma Rubenstein³, Jean Michel Molina^{3

4}, Constance Delaugerre^{1

4}, Marie Laure Chaix^{1

4}

Affiliations

¹ Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
² INSERM U976, Université Paris Cité, Hôpital Saint Louis, Paris 75010, France.
³ Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
⁴ INSERM U944, CNRS UMR 7212, Institut Universitaire d'Hématologie, Université Paris Cité, Hôpital Saint Louis, Paris 75010, France.

PMID: 37147875
DOI: 10.1093/jac/dkad135

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Anti-HIV Agents* / pharmacology
Anti-HIV Agents* / therapeutic use
Drug Resistance, Viral / genetics
HIV Infections* / drug therapy
HIV Integrase Inhibitors* / pharmacology
HIV Integrase Inhibitors* / therapeutic use
HIV Integrase* / genetics
HIV-1* / genetics
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Integrase Inhibitors / pharmacology
Integrase Inhibitors / therapeutic use
Integrases / genetics
Male
Mutation

Substances

Integrase Inhibitors
Anti-HIV Agents
Integrases
HIV Integrase Inhibitors
HIV Integrase
Heterocyclic Compounds, 3-Ring